MLR Review Process: A Complete Guide for Life Sciences Marketing in 2026

Life sciences companies face a unique challenge: every piece of marketing content must pass through Medical, Legal, and Regulatory (MLR) review before reaching customers. This process exists to protect patients and ensure claims meet strict compliance standards set by bodies like the FDA and EMA.

But MLR review often becomes a bottleneck. Marketing teams wait weeks for approval on materials that sales needs immediately. Legal flags claims that were pre-approved in similar campaigns. Medical reviewers request changes that contradict earlier feedback. Without a clear process, review cycles stretch from days into months, campaigns miss launch windows, and teams spend more time managing emails than creating content.

This is where a structured MLR review process makes the difference. A well-designed framework establishes clear roles, standardized workflows, and audit trails that satisfy regulators while moving materials through approval faster. This guide shows you exactly how to build and optimize an MLR process that protects compliance without sacrificing speed.

Key Takeaways

✓ MLR review is mandatory for all promotional materials in life sciences — any content that references products, indications, or outcomes must be approved by Medical, Legal, and Regulatory stakeholders before publication.

✓ The average MLR review cycle takes 15–45 days depending on material complexity and organizational maturity — companies with defined processes report 40–60% faster turnaround than those using ad-hoc email threads.

✓ Pre-review preparation cuts total cycle time in half — materials submitted with complete references, pre-approved claims libraries, and stakeholder context move through review 2–3x faster than incomplete drafts.

✓ Version control and audit trails are non-negotiable for regulatory defense — FDA inspections require proof of who approved what, when, and why for every published claim.

✓ Automation platforms designed for MLR workflows reduce manual coordination overhead by 70% — purpose-built tools track submissions, route to the right reviewers, and maintain compliance documentation automatically.

✓ Common delays stem from unclear roles, missing documentation, and reactive workflows — proactive governance frameworks that define approval authority and content tiers prevent 80% of bottlenecks before they occur.

What Is MLR Review and Why It Matters

MLR review is the formal approval process that life sciences companies use to ensure promotional materials meet medical accuracy standards, legal requirements, and regulatory guidelines before publication. The acronym stands for Medical, Legal, and Regulatory — the three core functions that evaluate every claim, image, and call-to-action in marketing content.

This process applies to any material that promotes a product or references clinical data: sales sheets, website pages, conference presentations, social media posts, email campaigns, patient education brochures, and video scripts. If a customer or healthcare provider will see it, MLR review is required.

The stakes are significant. Publishing unapproved content can trigger FDA warning letters, consent decrees, and financial penalties that reach into millions of dollars. More importantly, inaccurate claims can harm patients who make treatment decisions based on incomplete or misleading information. MLR review exists to prevent both outcomes.

For marketing operations managers, MLR review represents a critical coordination challenge. You must balance speed-to-market pressures from sales leaders with compliance requirements that cannot be compromised. The teams you coordinate — brand managers, medical affairs, legal counsel, regulatory experts — often have competing priorities and different definitions of what constitutes an acceptable claim.

Enterprise platforms like Veeva Vault PromoMats and Veeva Vault Medical are widely used by global pharma and med-tech as core repositories for promotional and medical content and approvals. These systems provide the infrastructure for managing submissions, tracking versions, and maintaining audit trails that satisfy regulatory inspections.

The challenge is not whether to implement MLR review — that decision is made by regulation. The challenge is how to design a process that protects compliance while enabling marketing teams to execute campaigns at the pace modern markets demand.

Step 1: Establish a Clear Governance Framework

Before any material enters review, you need a governance framework that defines who has approval authority, what criteria they apply, and how decisions are documented. Without this foundation, every submission becomes a negotiation about process rather than content.

Start by mapping stakeholder roles with precision. Medical reviewers verify clinical accuracy and ensure claims align with approved indications. Legal counsel assesses risk related to off-label promotion, comparative claims, and intellectual property. Regulatory experts confirm compliance with FDA guidance, EMA directives, and local market requirements. Each role has veto power over content within their domain.

Document approval authority in a RACI matrix (Responsible, Accountable, Consulted, Informed) that specifies who makes final decisions for different material types. For example, a product webpage might require Medical as Accountable for efficacy claims, Legal as Accountable for disclaimer language, and Regulatory as Consulted for overall compliance posture. This clarity prevents situations where three stakeholders each believe they have final say.

Define a Content Tiering System

Not all materials carry equal risk. A social media post with approved boilerplate language requires less scrutiny than a new disease awareness campaign with novel positioning. Build a tiering system that matches review rigor to material risk:

• Tier 1 (High Risk): New promotional campaigns, first-in-class positioning, comparative claims, materials for unbranded disease awareness. Requires full MLR committee review with documented sign-off from all three functions.

• Tier 2 (Moderate Risk): Adaptations of approved campaigns, localized versions of global materials, event presentations using approved slide decks. Requires Medical and either Legal or Regulatory approval depending on content type.

• Tier 3 (Low Risk): Minor updates to existing approved materials, reprints of approved content, materials using only pre-approved claims from the content library. May use expedited review or pre-approved templates.

This tiering system must be documented in your MLR standard operating procedure and communicated to all stakeholders. When marketing submits a Tier 2 material, reviewers understand the expected turnaround and depth of evaluation without needing to ask.

Set Approval Thresholds and Escalation Paths

Define what constitutes approval: does a material need unanimous sign-off, or can it proceed with majority approval and documented dissent? Establish thresholds for common scenarios. For instance, if Medical and Legal approve but Regulatory requests changes that would delay launch by two weeks, who has authority to make the trade-off decision?

Create escalation paths for deadlocks. If reviewers cannot reach consensus within the standard review window, the issue escalates to a predefined MLR committee chairperson or cross-functional leadership team. This prevents materials from sitting in limbo while stakeholders debate nuances.

Step 2: Build Pre-Approved Content Libraries

The fastest way to reduce MLR review time is to eliminate repetitive review of the same claims. Pre-approved content libraries — collections of claims, images, disclaimers, and boilerplate copy that have already passed full MLR review — allow marketing teams to assemble new materials without waiting for approval on every component.

Start by identifying your most frequently used claims. Pull the last six months of approved materials and catalog every product claim, indication statement, mechanism of action description, and safety disclaimer. Group identical or near-identical language together. You will likely find that 80% of your content reuses 20% of your claims.

Submit these high-frequency claims for MLR approval as standalone elements, not tied to specific campaigns. Once approved, store them in a searchable library with clear metadata: indication, product, claim type, approval date, and expiration date. Marketing teams can then reference approved claims by ID when creating new materials, significantly reducing the scope of new content requiring review.

Implement Version Control for Libraries

Pre-approved claims have expiration dates. When new clinical data emerges or regulatory guidance changes, previously approved language may no longer be compliant. Implement a version control system that tracks:

• Approval date and expiration date for every claim

• Source references (clinical trial data, package insert sections, regulatory submissions)

• Materials currently using each claim (for rapid recall if a claim is invalidated)

• Update history showing when and why claims were revised

Set automatic alerts for claims nearing expiration. Medical affairs should review expiring claims quarterly and either reapprove with updated references or retire them from the library. This proactive maintenance prevents the costly scenario where you discover mid-campaign that a key claim is no longer valid.

Create Approved Templates for Common Formats

Extend the pre-approval concept to entire document structures. If your team produces monthly email newsletters, create an approved template with fixed layout, disclaimer placement, and boilerplate sections. Marketing can then populate the template with pre-approved claims and submit only the new content for review, rather than the entire newsletter.

This strategy works particularly well for:

• Sales leave-behinds (fixed format, variable product information)

• Conference booth graphics (approved design system, updated event details)

• Social media post templates (character limits, required disclosures, brand voice)

• Email signature blocks (contact information, legal disclaimers, fair balance links)

Templates must be versioned and maintained just like claim libraries. When a template is updated — for example, to add a new required disclosure — all materials using that template should be flagged for review.

Step 3: Design Submission Workflows That Prevent Common Failures

Most MLR delays stem not from slow reviewers but from incomplete submissions. A material arrives without source references, or with claims that were never pre-cleared, or missing required disclaimers. Reviewers send it back, days are lost, and the cycle repeats. The solution is a submission checklist that validates completeness before materials enter review.

Build a submission form that captures all information reviewers need to evaluate content:

• Material type and tier: What is this (email, webpage, video) and what risk level does it carry?

• Target audience: Healthcare providers, patients, payers, internal sales force?

• Distribution channel: Paid media, owned properties, sales rep-distributed, event-based?

• Product and indication: Which products are mentioned and which indications are referenced?

• New vs. adapted: Is this net-new content or an adaptation of previously approved material? If adapted, provide the source material ID.

• Claims inventory: List every claim made about product efficacy, safety, or competitive positioning. For each claim, provide the reference source (clinical trial, package insert section, published study).

• Required reviewers: Which MLR functions must approve this material based on content type and tier?

• Deadline and rationale: When is approval needed and why? (Campaign launch date, event deadline, regulatory filing dependency)

This form should be digital, not a Word document attachment. Structured data enables automation that routes submissions to the right reviewers and flags missing information before human review begins.

Automate Reference Validation

One of the most common rejection reasons is inadequate source documentation. A marketer claims "Product X improved outcomes in 73% of patients" but provides only a vague reference to a clinical trial without specifying which endpoint or patient population.

Implement reference validation rules that check:

• Does the claim cite a specific source (NCT number, publication DOI, package insert section)?

• Is the source accessible to reviewers (link to study protocol, PDF of publication)?

• Does the claim language directly match the source, or is it an interpretation that requires Medical review?

If validation fails, the submission is automatically returned to the author with specific feedback on what is missing. This prevents the material from entering formal review until it meets minimum documentation standards.

Enable Parallel Review Where Appropriate

Sequential review — where Medical reviews first, then Legal, then Regulatory — extends cycle time unnecessarily for many materials. If a claim is already pre-approved and the only new element is a visual design, Legal and Medical can review simultaneously.

Design your workflow to route materials to multiple reviewers in parallel when:

• The material uses only pre-approved claims (reviewers focus on presentation, not content)

• Different reviewers have non-overlapping concerns (Legal reviews legal disclaimers, Medical reviews clinical claims, no dependency between them)

• The material is Tier 2 or Tier 3 (lower risk profile justifies faster process)

Reserve sequential review for Tier 1 materials where Medical findings might fundamentally change what Legal and Regulatory need to evaluate.

Step 4: Implement a Review Management System

Email threads are where MLR processes go to die. A marketer sends version 1 to Medical, Legal, and Regulatory. Medical replies with tracked changes. Legal replies to the original email with different edits. Regulatory asks a clarifying question. The marketer incorporates Medical's changes and sends version 2, but Legal's edits were in a separate thread and get missed. Three days later, Legal sees version 2 and asks why their feedback was ignored.

This chaos is eliminated by a purpose-built review management system that serves as the single source of truth for all submissions, feedback, versions, and approvals. Several categories of tools address this need:

When evaluating platforms, prioritize these capabilities:

• Version control: Every revision is saved with timestamp and author. Reviewers always see the latest version and can compare against previous drafts.

• Inline commenting: Reviewers add comments directly to specific text or images, visible to all stakeholders. No more "see my email from Tuesday" instructions.

• Approval routing: The system automatically notifies the next reviewer when the previous one approves, or escalates to the appropriate manager if deadlines are missed.

• Audit trails: Complete record of who submitted, who reviewed, what changed, when approvals were granted, and who downloaded the final approved file.

• Integration with content storage: Approved materials are automatically filed in the appropriate repository (DAM, content library, CRM) with metadata intact.

Step 5: Build Feedback Loops That Improve Process Quality

Even with strong governance and technology, MLR processes drift over time. Reviewers develop inconsistent standards. New team members interpret guidelines differently. Process exceptions become informal norms. Without active maintenance, what started as a streamlined workflow degrades into the chaos it replaced.

Implement quarterly process reviews that examine:

• Cycle time metrics: Average days from submission to approval, segmented by material tier and type. Are certain categories consistently slow? Why?

• Rejection rate: Percentage of submissions returned for incomplete information or non-compliance. High rejection rates indicate unclear submission guidelines or insufficient training.

• Revision count: How many back-and-forth cycles occur before approval? Materials requiring more than two revisions suggest misalignment on standards or unclear initial requirements.

• Expiration compliance: Percentage of in-market materials using expired claims. This metric identifies gaps in library maintenance and material recall processes.

• Stakeholder feedback: Anonymous surveys from Medical, Legal, Regulatory, and Marketing teams about process pain points and improvement opportunities.

Create Decision Logs for Precedent

Many MLR debates are not new. A question about whether a specific claim requires fair balance has likely been addressed in a previous review. But if that decision was made in an email thread and never documented, the next reviewer debates it again.

Maintain a decision log that captures:

• The question or issue that arose

• The material and context where it appeared

• The decision made and rationale

• The stakeholders who participated in the decision

• Date and any conditions or limitations on the precedent

When similar questions arise in future reviews, reviewers can search the decision log for precedent. This reduces inconsistency and speeds review by eliminating repeated debates.

Train Both Reviewers and Submitters Continuously

MLR training is often one-way: Marketing teams learn how to submit materials, but reviewers receive no training on how to provide effective feedback. This creates situations where a Legal reviewer flags "concerns" without explaining what would make the material acceptable, forcing multiple revision rounds.

Develop training for reviewers that covers:

• How to provide actionable feedback ("Remove this claim" vs. "This claim requires a qualifier about study limitations")

• When to escalate vs. when to approve with recommendations

• How to use the review management system effectively

• Common submission mistakes and how to coach authors to prevent them

For marketing submitters, provide training on:

• How to search and use the pre-approved claims library

• What level of detail reviewers need in source references

• How to interpret and incorporate feedback without triggering another review cycle

• When to request pre-review consultation vs. formal submission

Training should occur quarterly and be mandatory for any new team member involved in MLR processes.

Step 6: Optimize for Speed Without Compromising Compliance

After establishing governance, libraries, workflows, and systems, the final optimization focuses on reducing unnecessary delays without increasing risk. This requires distinguishing between delays that protect compliance (necessary) and delays that stem from coordination overhead (addressable).

Implement Service-Level Agreements by Material Tier

Establish target turnaround times for each material tier and hold reviewers accountable to those standards:

• Tier 1 materials: 10 business days for initial review, 5 days for revision review

• Tier 2 materials: 5 business days for initial review, 3 days for revision review

• Tier 3 materials: 3 business days for initial review, 1 day for revision review

These targets should be documented in the MLR SOP and tracked in the review management system. If a reviewer consistently misses SLAs, escalate to their manager to understand whether they lack bandwidth, need training, or are receiving too many expedite requests that disrupt prioritization.

Dedicate Reviewer Capacity

Many organizations assign MLR review as a secondary responsibility to full-time Medical, Legal, and Regulatory staff who already have primary duties. This leads to materials sitting in queues while reviewers handle higher-priority clinical, litigation, or submission work.

If your organization produces more than 50 materials per quarter requiring MLR review, dedicate at least one full-time equivalent in each function exclusively to promotional review. This person focuses only on MLR, becomes expert in the process and precedents, and has bandwidth to meet SLAs consistently.

For smaller teams, establish protected time blocks where reviewers focus exclusively on MLR submissions. A Medical reviewer might dedicate Tuesday and Thursday afternoons to promotional review, ensuring materials do not languish while they handle clinical study protocols.

Create an Expedite Process for Genuinely Time-Sensitive Materials

Every marketer believes their campaign is urgent. To prevent expedite requests from overwhelming reviewers and rendering SLAs meaningless, establish clear criteria for what qualifies as expedite-worthy:

• Regulatory-mandated material updates (e.g., new safety warnings that must be added to all promotional materials within a specific timeframe)

• Event-driven deadlines where missing the date means the material has no value (conference presentations, product launch announcements)

• Competitive response materials where delay creates measurable business risk

Expedite requests must be approved by a cross-functional MLR committee chair, not by the submitting marketer unilaterally. Approved expedites move to the front of the review queue with a 48-hour SLA, but authors must accept that accelerated review may result in more restrictive guidance than materials that go through standard timelines.

Common Mistakes to Avoid in MLR Review Processes

Even well-designed MLR processes encounter predictable failure modes. Understanding these patterns helps you build preventive controls rather than reacting after problems emerge.

Unclear Approval Authority

The most expensive mistake is ambiguity about who has final say. A material sits in review for weeks because Medical and Legal disagree on a claim, but no one knows whose judgment should prevail. Meanwhile, the campaign deadline passes and the sales team launches with unapproved materials to avoid further delay.

Prevention: Document approval authority in a RACI matrix by material type and content element. For efficacy claims, Medical is Accountable. For disclaimer language, Legal is Accountable. For overall regulatory posture, Regulatory is Accountable. When conflicts arise, escalate to the predefined MLR committee chair within 48 hours.

Treating All Materials Equally

Organizations that route every material through the same full-committee review process create artificial bottlenecks. A minor website typo fix waits in the same queue as a new disease awareness campaign, and reviewers spend time on low-risk materials that should have used expedited templates.

Prevention: Implement the content tiering system described in Step 1. Low-risk materials use pre-approved templates and streamlined review. High-risk materials get full scrutiny. This right-sizes review rigor to actual compliance risk.

No Version Control or Audit Trail

Email-based review processes fail catastrophically when the FDA requests documentation of who approved a specific claim in a material published two years ago. If your audit trail consists of searching email archives for the right thread, you cannot satisfy regulatory defense requirements.

Prevention: Use a purpose-built review management system that automatically logs every submission, revision, comment, approval, and file access. Audit trails should be immutable and exportable for regulatory inspection.

Reactive Claim Management

Many teams discover mid-campaign that a key claim they have been using for months is no longer supported by current clinical data. All materials using that claim must be recalled, reviewed, and republished. The cost and delay are enormous.

Prevention: Implement proactive claim library maintenance with expiration dates, quarterly Medical affairs review of all active claims, and automatic alerts when materials use claims nearing expiration. This shifts from reactive crisis management to proactive governance.

Insufficient Training for Submitters

High rejection rates waste everyone's time. If 40% of submissions are returned for incomplete documentation or use of non-approved claims, the problem is not reviewers being difficult — the problem is submitters do not understand requirements.

Prevention: Mandatory training for all marketing team members who submit materials for MLR review. Include practical exercises like "here is an incomplete submission — what is wrong with it?" and "here is ambiguous feedback — how do you incorporate it?" Quarterly refresher training keeps standards consistent as teams grow.

No Escalation Path for Deadlocks

When Medical, Legal, and Regulatory cannot reach consensus, materials sit in limbo indefinitely unless someone has authority to make the final call. Without a documented escalation path, deadlocks become territorial disputes rather than process issues.

Prevention: Define an escalation committee (typically cross-functional leadership with representation from Medical, Legal, Regulatory, and Commercial) that reviews deadlocked materials within five business days and issues binding decisions. Document the decision rationale for future precedent.

Tools That Help with MLR Review Processes

The right technology stack reduces coordination overhead, enforces process compliance, and provides the audit trails regulators require. Here is how leading platforms address specific MLR challenges:

Improvado: Marketing Ops + Compliance Data Integration

Improvado connects marketing campaign performance data to MLR approval metadata, enabling teams to track which approved materials are currently in-market, flag campaigns using expired claims, and provide audit trails that link material performance to compliance review history.

Key MLR capabilities:

• Connects to 1,000+ marketing data sources and overlays compliance metadata

• Tracks approval dates, expiration dates, and version history for all materials

• Alerts when live campaigns use materials with expired MLR approval

• Provides unified reporting that shows campaign performance alongside compliance status

• Marketing Data Governance engine validates data quality and flags anomalies before they reach reports

Best for: Marketing operations teams that need to connect MLR approval workflows to campaign analytics, performance tracking, and budget governance at enterprise scale. Particularly valuable for organizations running hundreds of campaigns across multiple markets where manual tracking of material approval status becomes impossible.

Implementation: Custom pricing based on data source count and governance requirements. Typically operational within a week with dedicated customer success support.

Veeva Vault PromoMats: Purpose-Built Life Sciences Content Management

Veeva Vault PromoMats is designed specifically for pharmaceutical promotional review and approval. It includes pre-configured workflows that match standard pharma MLR processes, claim libraries with expiration tracking, and integration with Veeva CRM for distribution control.

Key features: MLR workflow templates, claim library management, multichannel approval tracking, expiration alerts, audit-ready reporting, integration with Veeva Medical for scientific content alignment.

Best for: Large pharmaceutical and medical device companies with complex multi-country compliance requirements and existing Veeva ecosystem investments.

Limitation: Implementation complexity and cost make it less suitable for smaller biotech or med-tech companies. Requires significant configuration and change management.

Adobe Workfront: Enterprise Work Management with Custom Workflows

Workfront provides flexible workflow automation that can be configured for MLR processes. Strong integration with Adobe Creative Cloud makes it natural for organizations with creative teams using Adobe tools.

Key features: Custom workflow builder, approval routing, version control, proofing tools with inline markup, integration with Adobe Experience Manager for final asset storage.

Best for: Organizations with strong Adobe ecosystem presence that need custom MLR workflows beyond what pre-built tools offer. Particularly effective for creative-heavy organizations producing video, interactive content, and rich media.

Limitation: Requires internal configuration expertise to build MLR-specific workflows. Not pre-configured for life sciences compliance requirements.

Wrike: Marketing Project Management with Approval Workflows

Wrike offers marketing-first project management with built-in approval workflows, custom forms for submission intake, and Gantt charts for campaign timeline management.

Key features: Approval workflows, custom intake forms, proofing and markup, integration with Google Workspace and Microsoft 365, Gantt charts for tracking MLR timelines against campaign launches.

Best for: Mid-market life sciences companies prioritizing ease of use and fast implementation. Good balance of structure and flexibility for teams that need MLR capabilities without enterprise complexity.

Limitation: Less robust audit trail capabilities than purpose-built compliance platforms. May require supplementary documentation processes for regulatory defense.

Monday.com: Visual Work Management with No-Code Automation

Monday.com provides highly customizable workflow automation using a visual no-code builder. Teams can create MLR approval boards, automated routing, and status dashboards without IT dependency.

Key features: No-code workflow automation, visual status boards, integration with storage and communication tools, custom forms for submission intake, timeline views for deadline tracking.

Best for: Teams seeking high customization with minimal IT involvement. Particularly effective for smaller biotech companies or divisions within larger organizations that need to implement MLR processes quickly.

Limitation: Flexibility can become a liability if teams build overly complex custom workflows that become difficult to maintain. Requires discipline to establish and enforce standards.

How to Integrate MLR Tools with Your Existing Marketing Stack

MLR review systems do not operate in isolation. They must connect to your content creation tools (where materials are authored), your content storage systems (where approved materials live), your CRM and marketing automation platforms (which distribute materials), and your analytics systems (which measure material performance).

The most effective architecture treats the MLR review platform as the control point in a hub-and-spoke model:

• Authoring tools (Adobe Creative Cloud, Microsoft Office, video editing platforms) feed draft materials into the review system for approval.

• Review platform manages workflow, versions, approvals, and audit trails.

• Approved materials are automatically pushed to digital asset management (DAM) systems or content libraries with metadata tags indicating approval status, expiration date, and usage restrictions.

• Distribution platforms (CRM, marketing automation, website CMS) pull only approved materials from the DAM, preventing accidental use of unapproved content.

• Analytics systems (like Improvado) connect material performance back to approval metadata, enabling analysis of which material types or claim categories drive the best outcomes.

This integration prevents several common failures: marketers bypassing approval by uploading content directly to distribution channels, sales teams using outdated versions because they cannot find the latest approved file, and compliance teams lacking visibility into which materials are currently in-market.

Implementation requires API connections between systems and governance rules about what can be published without flowing through the MLR hub. Work with your IT and compliance teams to map data flows and enforce controls at the system level, not just the policy level.

Measuring MLR Process Performance

You cannot improve what you do not measure. Establish quantitative metrics that track both process efficiency and compliance quality:

Efficiency Metrics

Compliance Metrics

Review these metrics monthly in cross-functional MLR committee meetings. Investigate outliers: if Tier 2 cycle times suddenly spike, why? If rejection rate increases, is it a training issue or a change in reviewer interpretation? Metrics should drive process improvements, not be filed away in reports no one reads.

Conclusion

MLR review does not have to be the bottleneck that delays every campaign and frustrates every stakeholder. With clear governance, pre-approved content libraries, structured workflows, purpose-built technology, and continuous process improvement, you can reduce approval cycles by 40–60% while strengthening compliance.

The key is treating MLR as a system, not a series of ad-hoc approvals. Every component — governance framework, submission requirements, review routing, feedback loops, metrics — must work together to move materials through approval faster without compromising the medical accuracy, legal defensibility, and regulatory compliance that protect both your organization and the patients you serve.

Start with the governance framework in Step 1. Document roles, approval authority, and material tiers. That foundation enables everything else: pre-approved libraries that reduce repetitive review, submission workflows that prevent incomplete materials from entering the queue, technology that enforces process and creates audit trails, and feedback loops that continuously improve quality and speed.

The result is a competitive advantage. While competitors wait weeks for approval, your campaigns launch on time. While others scramble to recall materials with expired claims, your proactive governance prevents the crisis. While others face regulatory scrutiny over inadequate documentation, your audit trails provide complete defense.

Frequently Asked Questions

Is MLR review required by law or just industry best practice?

MLR review is not explicitly mandated by a single regulation, but it is effectively required by the cumulative weight of FDA enforcement actions, consent decrees, and industry guidance. The FDA holds companies responsible for ensuring all promotional materials are truthful, balanced, and substantiated by adequate evidence. Failure to implement a review process that verifies these standards results in warning letters, injunctions, and financial penalties. While the specific term "MLR review" does not appear in regulation, the underlying requirement — that Medical, Legal, and Regulatory expertise validate promotional content before publication — is well-established through decades of enforcement history. Companies that skip this process face material regulatory risk.

What is a reasonable cycle time for MLR review?

Cycle time depends on material complexity and risk tier. Industry benchmarks suggest 10–15 business days for high-risk Tier 1 materials (new campaigns, comparative claims, disease awareness content), 5–7 days for moderate-risk Tier 2 materials (adaptations of approved campaigns, event presentations), and 2–3 days for low-risk Tier 3 materials (minor updates, pre-approved template usage). Organizations with mature processes and dedicated reviewer capacity achieve these targets consistently. Companies using ad-hoc email-based review often see cycles stretch to 30–45 days due to coordination overhead and unclear approval authority. If your average cycle time exceeds these ranges, focus on the governance and workflow improvements outlined in Steps 1–3 of this guide.

Can we expedite every submission to speed up the process?

No. Expedite processes only work when used sparingly for genuinely time-sensitive materials. If every submission is labeled urgent, reviewers have no signal about what actually requires immediate attention, and expedite requests lose meaning. Establish clear criteria for what qualifies as expedite-worthy — regulatory-mandated updates with compliance deadlines, event-driven materials where missing the date eliminates the value, or competitive response scenarios with measurable business risk. Expedite requests should represent less than 10% of total submissions and require approval from an MLR committee chair, not the submitting marketer unilaterally. For all other materials, improve standard cycle times through better governance, pre-approved content libraries, and dedicated reviewer capacity rather than trying to expedite everything.

How do we know when a pre-approved claim expires?

Every claim in your pre-approved library should have an explicit expiration date based on the underlying source data. Claims sourced from clinical trials are typically valid until new data emerges or regulatory guidance changes. Claims from package inserts are valid until the label is updated. Establish a review cadence — quarterly is common — where Medical affairs evaluates all active claims for continued validity. The review checks whether new clinical data has been published, whether regulatory guidance has changed, and whether the claim remains consistent with current medical consensus. Claims nearing expiration should trigger automatic alerts to Medical affairs for proactive review, and to marketing operations to identify which materials use those claims. This prevents the costly scenario where you discover mid-campaign that a claim is no longer valid. Version control systems should track expiration dates and make expired claims unsearchable so marketers cannot accidentally use them in new materials.

Our team is too small to dedicate full-time MLR reviewers. What do we do?

Small organizations can implement effective MLR processes without full-time dedicated reviewers by using time-blocking and external resources strategically. Establish protected time blocks where Medical, Legal, and Regulatory staff focus exclusively on promotional review — for example, Tuesday and Thursday afternoons. During these windows, they do not take meetings or handle other responsibilities, ensuring consistent availability for review. Pair this with strong use of pre-approved content libraries and templates to reduce the volume of materials requiring full review. For specialized expertise — particularly Legal and Regulatory review — consider retaining external consultants who provide fractional support on a retainer basis. This gives you access to experienced reviewers without the overhead of full-time headcount. The key is predictability: if marketing knows that materials submitted Monday will be reviewed Thursday, they can plan campaigns accordingly rather than facing unpredictable multi-week delays.

What happens when Medical and Legal cannot agree on a claim?

Disagreements between MLR functions should escalate to a predefined committee or authority with binding decision power. Most organizations establish an MLR committee chair — often a senior leader with cross-functional credibility — who reviews deadlocked materials and issues final decisions within a defined timeframe (typically 48–72 hours after escalation). The committee documents the rationale for the decision, the stakeholders who participated, and any conditions or limitations on the precedent. This decision becomes part of the decision log for future reference. The goal is not to override expert judgment but to prevent materials from sitting in limbo indefinitely while stakeholders debate nuances. If disagreements occur frequently on the same types of claims, that signals a need for clearer guidelines or precedent documentation. Quarterly process reviews should examine escalation frequency and reasons to identify patterns requiring policy clarification.

Do social media posts require the same MLR review as sales brochures?

Yes, if the social media content is promotional. The channel does not change the compliance requirement. A tweet that mentions product benefits, clinical outcomes, or competitive comparisons is promotional content and must pass MLR review before publication. The difference is in process design, not whether review is required. Social media posts should use pre-approved content templates and claim libraries to enable fast turnaround. Many organizations create libraries of approved social posts that marketing can schedule directly without per-post review, refreshing the library quarterly with new approved content. Responses to user comments that stay within approved language can also use expedited workflows. The key control is preventing marketers from improvising promotional claims in real-time without Medical, Legal, and Regulatory validation. If your organization struggles with social media MLR timelines, focus on building robust pre-approved libraries rather than trying to review every individual post.